Relationship between the effect of eldecalcitol and serum 25(OH)D level

被引:4
作者
Takano, Toshiyuki [1 ]
Kondo, Satoshi [1 ]
Saito, Hitoshi [1 ]
Matsumoto, Toshio [2 ]
机构
[1] Chugai Pharmaceut Co Ltd, Tokyo 1038324, Japan
[2] Univ Tokushima, Grad Sch Hlth Biosci, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan
关键词
Osteoporosis; Eldecalcitol; Fracture; Vitamin D; 25(OH)D; VITAMIN-D; OSTEOPOROSIS; WOMEN; RISK; FRACTURES; ANALOG;
D O I
10.1016/j.jsbmb.2013.11.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In previous studies, we demonstrated that 12-month treatment with 0.75 mu g/day eldecalcitol increased bone mineral density in osteoporotic patients regardless of serum 25-hydroxyvitamin D (25(OH)D) level, and in a 3-year randomized double-blind clinical trial, eldecalcitol significantly reduced the incidences of vertebral and wrist fractures compared to alfacalcidol. However, it remains unclear whether the fracture risk reduction by eldecalcitol is affected by serum 25(OH)D. In the fracture prevention trial, patients with low 25(OH)D level at baseline were supplemented with 400 IU/day native vitamin D3. In the current study, patients from that trial were divided according to the tertiles of serum 25(OH)D level at 6 months after treatment initiation. The increases in lumbar and hip BMD by eldecalcitol were significantly higher in all tertiles than those by alfacalcidol. The incidences of vertebral and osteoporotic fractures tended to be lower in each tertile of the eldecalcitol-treated group than in the corresponding tertile of the alfacalcidol-treated group, with the exception of vertebral fractures in the low tertile. We also investigated whether eldecalcitol treatment affected levels of serum 25(OH)D, serum 1,25(OH)2D, and parathyroid hormone in patients without vitamin D supplementation. With eldecalcitol treatment, serum 1,25(OH)2D concentration was reduced by approximately 50%, whereas serum levels of parathyroid hormone and 25(OH)D were not affected. The major findings of the present study were that eldecalcitol did not affect serum 25(OH)D levels, and that it reduced the incidence of osteoporotic fractures and increased BMD in comparison with alfacalcidol regardless of serum 25(OH)D level within the range of serum 25(OH)D concentrations at or higher than 20 ng/mL. Whether eldecalcitol is similarly effective at vitamin D deficient serum 25(OH)D levels remains to be clarified. This article is part of a Special Issue entitled 'Vitamin D Workshop'. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:124 / 127
页数:4
相关论文
共 11 条
[1]   What is new in vitamin D: 2006-2007 [J].
Bikle, Daniel D. .
CURRENT OPINION IN RHEUMATOLOGY, 2007, 19 (04) :383-388
[2]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[3]   Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial [J].
Ettinger, B ;
Black, DM ;
Mitlak, BH ;
Knickerbocker, RK ;
Nickelsen, T ;
Genant, HK ;
Christiansen, C ;
Delmas, PD ;
Zanchetta, JR ;
Stakkestad, J ;
Glüer, CC ;
Krueger, K ;
Cohen, FJ ;
Eckert, S ;
Ensrud, KE ;
Avioli, LV ;
Lips, P ;
Cummings, SR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :637-645
[4]   Differential time course of induction of 1α,25-dihydroxyvitamin D3-24-hydroxylase mRNA expression in rats by 1α,25-dihydroxyvitamin D3 and its analogs [J].
Furuichi, T ;
Kawata, S ;
Asoh, Y ;
Kumaki, K ;
Ohyama, Y .
LIFE SCIENCES, 1997, 62 (05) :453-459
[5]   Eldecalcitol is less effective in suppressing parathyroid hormone compared to calcitriol in vivo [J].
Harada, Suguru ;
Takeda, Satoshi ;
Uno, Akiko ;
Takahashi, Fumiaki ;
Saito, Hitoshi .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2010, 121 (1-2) :281-283
[6]   Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - A randomized controlled trial [J].
Harris, ST ;
Watts, NB ;
Genant, HK ;
McKeever, CD ;
Hangartner, T ;
Keller, M ;
Chesnut, CH ;
Brown, J ;
Eriksen, EF ;
Hoseyni, MS ;
Axelrod, DW ;
Miller, PD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (14) :1344-1352
[7]   Minimum Required Vitamin D Level for Optimal Increase in Bone Mineral Density with Alendronate Treatment in Osteoporotic Women [J].
Ishijima, Muneaki ;
Sakamoto, Yuko ;
Yamanaka, Makoto ;
Tokita, Akifumi ;
Kitahara, Keiichiro ;
Kaneko, Haruka ;
Kurosawa, Hisashi .
CALCIFIED TISSUE INTERNATIONAL, 2009, 85 (05) :398-404
[8]   A new active vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patients [J].
Kubodera, N ;
Tsuji, N ;
Uchiyama, Y ;
Endo, K .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 88 (02) :286-289
[9]   A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures - A randomized, active comparator, double-blind study [J].
Matsumoto, Toshio ;
Ito, Masako ;
Hayashi, Yasufumi ;
Hirota, Takako ;
Tanigawara, Yusuke ;
Sone, Teruki ;
Fukunaga, Masao ;
Shiraki, Masataka ;
Nakamura, Toshitaka .
BONE, 2011, 49 (04) :605-612
[10]   Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism [J].
Matsumoto, Toshio ;
Takano, Toshiyuki ;
Yamakido, Shinji ;
Takahashi, Fumiaki ;
Tsuji, Naoki .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2010, 121 (1-2) :261-264